Percutaneous image-guided cryoablation of central renal tumors with temporary balloon occlusion has a technical success rate of 93%.
Primary and secondary efficacy rates of the technique are 93% and 100%, respectively.
Percutaneous image-guided cryoablation of central renal tumors with temporary balloon occlusion has a minimal effect on renal function.
Major complication (CIRSE Classification ≥ 3) rate is 21%, including fever requiring hospital stay > 3 days and segmental renal artery pseudoaneurysm.
The purpose of this study was to report the technical feasibility and outcomes of percutaneous image-guided cryoablation with temporary balloon occlusion of the renal artery for the treatment of central renal tumors.
Materials and methods
All consecutive patients with central renal tumors treated with cryoablation and temporary renal artery occlusion from January 2017 to October 2021 were retrospectively included. Patient demographics, tumor's characteristics, procedural data, technical success, primary and secondary clinical efficacy, complications (according to Cardiovascular and Interventional Radiology Society of Europe [CIRSE] classification) and follow-up were investigated.
A total of 14 patients (8 men, 6 women; mean age 72.4 years ± 21.4 [SD] years; age range: 42–93 years) with 14 central renal tumors (median size, 32 mm; IQR: 23.5, 39.5 mm; range: 13–50 mm) were treated with percutaneous image-guided cryoablation and temporary balloon occlusion of the renal artery. Technical success was 13/14 (93%), with 1/14 (7%) failure of vascular access. A median of 4 cryoprobes (IQR: 3, 4.75) were inserted and protective hydrodissection was performed in 11/14 (79%) patients. Median time to perform cryoprobes insertion, hydrodissection and vascular access was 26.5 min (IQR: 18, 35 min), 10 min (IQR: 10, 17 min) and 30 min (IQR: 20, 45 min) respectively. Median duration of the whole intervention was 150 min (IQR: 129, 180 min; range: 100–270 min). Median hospital stay was 2.5 days (IQR: 2, 4 days; range: 2–14 days). Major complications occurred in 3/14 (21%) patients. Primary efficacy rate was 93% (13/14 patients). Median oncological follow-up was 25 months (IQR: 11, 33 months; range: 6–39 months). One patient experienced renal tumor recurrence at 14-months of follow-up, which was successfully treated with repeat cryoablation.
Percutaneous image-guided cryoablation of renal tumors with temporary balloon occlusion of the renal artery is technically feasible, with a high technical success rate and paths the way for percutaneous treatment of central renal tumors.Le texte complet de cet article est disponible en PDF.
Keywords : Cryoablation, Endovascular procedure, Malignant neoplasm, Renal cell carcinoma
Abbreviations : CIRSE, CT, eGFR, IQR, LRFS, SD